Literature DB >> 15280785

Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less.

Elena Ferrer1, Elena Santamariña, Pere Domingo, Emilio Fumero, Esteban Ribera, Hernando Knobel, Juan Carlos Lopez, Ana Barrios, Daniel Podzamczer.   

Abstract

We retrospectively evaluated the effectiveness of nevirapine-containing regimens in 118 naive patients initiating highly active antiretroviral therapy with CD4 cell counts S 200 cells/jl. After 24 months, 51% of patients continued nevirapine, 43 and 83% had viral loads < 50 copies/ml by intent-to-treat and on-treatment analyses, and a mean increase of +246 CD4 cells/microl occurred. More than 80% of patients who continued with nevirapine had viral loads < 50 copies/ml and CD4 cell counts > 200 cells/pl.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15280785     DOI: 10.1097/01.aids.0000131381.07609.19

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  3 in total

1.  Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine, and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: A prospective study.

Authors:  Weerawat Manosuthi; Somnuek Sungkanuparph; Somsit Tansuphaswadikul; Wisit Prasithsirikul; Chatiya Athichathanabadi; Sirirat Likanonsakul; Achara Chaovavanich
Journal:  Curr Ther Res Clin Exp       Date:  2008-02

2.  Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3.

Authors:  Weerawat Manosuthi; Sukanya Chimsuntorn; Sirirat Likanonsakul; Somnuek Sungkanuparph
Journal:  AIDS Res Ther       Date:  2007-03-13       Impact factor: 2.250

3.  Kaposi's sarcoma manifested as lower gastrointestinal bleeding in a HIV/HBV-co-infected liver cirrhosis patient: A case report.

Authors:  Qi-Hui Zhou; Yong-Zheng Guo; Xia-Hong Dai; Biao Zhu
Journal:  World J Clin Cases       Date:  2019-10-06       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.